Prevalence of Fabry disease in dialysis patients: Japan Fabry disease screening study (J-FAST). (Q41562385)

3 October 2017

Prevalence of Fabry disease in dialysis patients: Japan Fabry disease screening study (J-FAST). (English)

1 reference

3 October 2017

0 references

1 reference

Osamu Saito

1

1 reference

3 October 2017

Eiji Kusano

2

1 reference

3 October 2017

Tetsu Akimoto

3

1 reference

3 October 2017

Yasushi Asano

4

1 reference

3 October 2017

Teruo Kitagawa

5

1 reference

3 October 2017

Ken Suzuki

6

1 reference

3 October 2017

Nobuyuki Ishige

7

1 reference

3 October 2017

Takashi Akiba

8

1 reference

3 October 2017

Akira Saito

9

1 reference

3 October 2017

Eiji Ishimura

10

1 reference

3 October 2017

Motoshi Hattori

11

1 reference

3 October 2017

Akira Hishida

12

1 reference

3 October 2017

Chu Guili

13

1 reference

3 October 2017

Hiroki Maruyama

14

1 reference

3 October 2017

Masahisa Kobayashi

15

1 reference

3 October 2017

Touya Ohashi

16

1 reference

3 October 2017

Ichiro Matsuda

17

1 reference

3 October 2017

Yoshikatsu Eto

18

1 reference

3 October 2017

22 July 2015

1 reference

3 October 2017

10

1 reference

Clinical and experimental nephrology

inferred from page(s)

published in

1 reference

3 October 2017

20

1 reference

3 October 2017

284-293

1 reference

3 October 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1007/s10157-015-1146-7

3 October 2017

0 references

cites work

Fabry's Disease: Alpha-Galactosidase Deficiency

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1146-7

Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1146-7

Renal disease in Fabry patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1146-7

Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1146-7

alpha-Galactosidase A deficiency in Dutch patients on dialysis: a critical appraisal of screening for Fabry disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1146-7

Significance of screening for Fabry disease among male dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1146-7

A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1146-7

Prevalence and cardiovascular features of Japanese hemodialysis patients with Fabry disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1146-7

Two-tier approach for the detection of alpha-galactosidase A deficiency in a predominantly female haemodialysis population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1146-7

Frequency of Fabry disease in male and female haemodialysis patients in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1146-7

Screening of male dialysis patients for fabry disease by plasma globotriaosylsphingosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1146-7

Overview of regular dialysis treatment in Japan (as of 31 December 2009).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1146-7

Non-invasive high-risk screening for Fabry disease hemizygotes and heterozygotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1146-7

Mutations of the GLA gene in Korean patients with Fabry disease and frequency of the E66Q allele as a functional variant in Korean newborns.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1146-7

Anderson-Fabry disease: a multiorgan disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1146-7

Enzyme therapy in Fabry disease: differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic alpha-galactosidase A isozymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1146-7

Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1146-7

Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1146-7

Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1146-7

Diagnosis of Fabry disease: usefulness of the clinical investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-015-1146-7

Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study

21 January 2018

1 reference

12 December 2020

The frequency of Fabry disease with the E66Q variant in the α-galactosidase A gene in Japanese dialysis patients: a case report and a literature review

1 reference

12 December 2020

Fabry disease in patients with end-stage renal failure: the potential benefits of screening

1 reference

12 December 2020

Results of a nationwide screening for Anderson-Fabry disease among dialysis patients

1 reference

12 December 2020

Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype

1 reference

12 December 2020

No accumulation of globotriaosylceramide in the heart of a patient with the E66Q mutation in the α-galactosidase A gene

1 reference

12 December 2020

Identification of Fabry's disease by the screening of alpha-galactosidase A activity in male and female hemodialysis patients.

1 reference

12 December 2020

Identification of a novel mutation and prevalence study for fabry disease in Japanese dialysis patients

1 reference

12 December 2020

Replacement Therapy for Inherited Enzyme Deficiency

1 reference

12 December 2020

High-throughput screening identified disease-causing mutants and functional variants of α-galactosidase A gene in Japanese male hemodialysis patients

1 reference

12 December 2020

Fabry disease in hemodialysis patients in southern Brazil: prevalence study and clinical report

1 reference

12 December 2020

Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes

1 reference

12 December 2020

Enzyme replacement therapy for Fabry's disease

1 reference

12 December 2020

Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease

1 reference

12 December 2020

10.1007/S10157-015-1146-7

Identifiers

DOI

1 reference

3 October 2017

1 reference